Global developmental delay (GDD) and intellectual disability (ID) affect an estimated 1% to 3% of children worldwide and are among the most common neurodevelopmental conditions encountered in ...

A new analysis from the Transgenerational Effect on Adult Morbidity (TEAM) Study has found that maternal hyperglycemia in the third trimester of insulin-dependent diabetic pregnancies is associated ...

Children exposed in utero to certain synthetic chemicals known as PFAS had higher blood pressure in adolescence, according to findings published in the Journal of the American Heart Association and ...

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

As summer approaches, pediatric dermatologist John Browning, MD, Chief of Dermatology at Children’s Hospital of San Antonio is reminding families to stay vigilant about sun safety, especially for ...

The FDA has extended its review of Incyte’s supplemental New Drug Application (sNDA) for ruxolitinib cream 0.75% (Opzelura) for the treatment of mild to moderate atopic dermatitis (AD) in children ...

The FDA’s June 9, 2025, approval of clesrovimab (Enflonsia; Merck) to prevent respiratory syncytial virus (RSV) in infants could have potential ripple effects of RSV prevention—not only in reducing ...

Researchers at Rutgers Health have proposed a new approach to addressing Sudden Unexpected Infant Death (SUID)—caffeine. In a hypothesis published in the Journal of Perinatology, they suggest caffeine ...

Michael O. Daines, MD, division chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine and principal investigator of the phase 3 trial evaluating Panzyga for ...

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents. A large cohort study published in JAMA has found that both high ...

John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent non-steroidals, and what questions to ask patients in office. John Browning, MD, Chief of Dermatology at ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...